study, with the phenotype for IMM defined as gross muscle atrophy and lymphocytic myofiber infiltrates. Subsequent sequencing of genes within the associated locus identified a missense mutation in a highly conserved region of MYH1 that segregated with disease status. 3 The MYH1 gene encodes myosin heavy chain 2X, which is found in fast twitch type 2X muscle fibers. In the absence of inflammation, the proportion of type 2X muscle fibers in IMM muscle was within normal limits. However, in IMM horses with gross muscle atrophy, lymphocytes infiltrated type 2X myofibers and fewer type 2X fibers were present. 3 The equine MYH1 mutation is the first reported disease-causing mutation in MYH1 in any species. The biological relevance of the E321G MYH1 mutation is strengthened by the fact that glutamic acid (E) is highly conserved across species (Sus, Bos, Homo, Oryctol, Rat, and Canis) and present in the corresponding position of the myosin heavy chain of type 2A, perinatal, extraocular, embryonic, and cardiac/slow myosin in many species, including the horse. 4 The most common muscle disorder in QHs, rhabdomyolysis, shares the characteristic of increased serum creatine kinase (CK) activity with IMM. 5 Causes of rhabdomyolysis range from toxins such as hypoglycin A to genetic disorders such as type 1 polysaccharide storage myopathy (PSSM1) and malignant hyperthermia (MH). 6 However, in many cases of rhabdomyolysis, the specific etiology is unrecognized. 5 The features distinguishing rhabdomyolysis from IMM are the lack of rapid-onset muscle atrophy and the absence of lymphocytic infiltrates in gluteal or epaxial muscle biopsy samples. 1, 5, 7 A diagnosis of IMM in horses could be missed, however, when the primary presenting complaint is rhabdomyolysis because the most common muscle biopsy sample submitted for evaluation of rhabdomyolysis is from the semimembranosus (SM) or semitendinosus (ST) muscles. These muscles often lack lymphocytic infiltrates in IMM horses. 1, 2 We hypothesized that the E321G MYH1 mutation would be prevalent in horses presenting with nonexertional rhabdomyolysis (nonER) regardless of whether or not horses presented with or without muscle atrophy. The purpose of our retrospective study was to determine if the E321G MHY1 mutation associated with IMM also was associated with the phenotype of rhabdomyolysis with or without gross muscle atrophy and with or without lymphocytic infiltrates in muscle samples.
The objectives were: (1) to determine the prevalence of the MYH1 mutation in QH presenting with ER with or without gross muscle atrophy; (2) to determine the prevalence of the MYH1 mutation in young QH presenting with nonER regardless of gross muscle atrophy; and (3) to characterize the histopathologic findings in muscle biopsy samples of horses with rhabdomyolysis and the MYH1 mutation.
| MATERIALS AND METHODS

| Horses
| Controls
The prevalence of the MYH1 mutation in healthy QH was determined in 72 healthy QH, which were housed on farms across the US, had no known history of muscle disease and had DNA available for testing (Table 1) . the GYS1 mutation. 8 If available in the database, the genotype for the C7360G RYR1 mutation for malignant hyperthermia was noted. 
| Exertional rhabdomyolysis
| Nonexertional rhabdomyolysis
Records and the sample repository of the NMDL were reviewed from 1995 to 2017 to identify all QH < 5 years of age that had a history consistent with nonER, documented serum CK activity ≥5000 U/L and hair, buffy coat, or muscle samples available for DNA extraction.
If available in the database, the R309H GYS1 genotype for PSSM1
was noted and, if unavailable, horses were genotyped for the GYS1 mutation. 8 All horses with the GYS1 mutation were excluded from further analysis to ensure that PSSM1 did not contribute to nonER. If Horses with ER did not have any restrictions on age for inclusion whereas nonER horses were selected with an upper age-limit of 4 years of age. Different superscripts indicate significant differences within columns where ER and for nonER analyzed separately. Abbreviation: GYS1, glycogen synthase 1.
available in the database, the genotype for C7360G RYR1 was noted and, if glycogen depletion had been noted in the histochemical evaluation, analysis was performed for C7360G RYR1. 9 Clinical signs recorded by the referring veterinarian were tabulated and compared between genotypes.
| Histopathology
The sample repository was reviewed to identify those horses that had Images were captured and pseudocolored composites generated.
| Genotyping 2.3.1 | DNA isolation
The DNA was isolated from hair bulbs, buffy coat, whole blood, or muscle tissue by Gentra Puregene Kits (Qiagen; Germantown, Maryland) and quantified to ensure ≥10 ng/μL of DNA was available with a 260/280 ratio of ≥1.8 and ≤ 2.2. DNA for PCR reactions was diluted to 35 AE 25 ng/μL. 
| Polymerase chain reaction
| Pyrosequencing
Forward, reverse, and sequencing primers were designed by Pyrose- 
| Data analysis
Normality was tested via a Shapiro-Wilk normality test. A 1-way analysis of variance (ANOVA) was used to compare ages of horses. A chisquare test was used to compare the genotypes of random QH controls, ER and nonER horses with specific clinical signs as well as to compare the number of horses with lymphocytic infiltrates and large myofiber glycogen depletion. Scores for muscle histopathology were compared by Mann-Whitney test. Serum CK and AST activities in nonER horses were log transformed to normalize data and compared by one-way ANOVA. Statistical analyses were performed in GraphPad Prism 7 (GraphPad Prism version 7, GraphPad Software, La Jolla, California, www.graphpad.com). Results are presented as mean and standard deviations (SD). Significance was set at P < .05.
| RESULTS
There were 72 control horses, similar in age to ER horses (Table 1) .
Fifty-six ER horses without atrophy and 85 ER horses with atrophy (62 GYS1 negative, 23 GYS1 positive) were included in the study (Table 1) . Among GYS1-animals, horses with muscle atrophy were significantly younger than horses without muscle atrophy (P < .006).
There were 165 nonER horses, 42 with atrophy and 123 without atrophy ( Table 1 ). The mean age of nonER horses was only 1 year despite inclusion criteria that specified all nonER horses <5 years of age.
Control genotypes: The MYH1 mutation was present in 5% of controls (4/72).
| Exertional rhabdomyolysis
| ER genotypes
The MYH1 mutation was present in 2% (1/56) of ER horses without gross muscle atrophy ( Figure 1 ). The MYH1 mutation was present in 29% (25/85) of ER with atrophy including both those GYS1+ (5/23; 22%) and GYS1-(20/62; 32%), which was a significantly higher proportion than controls (P < .001; Figure 1 ). The mutation for C7360G
RYR1 was not found in any of the 30 ER horses tested.
| ER histopathology
Slides from 61 muscles were available for evaluation. Only 7 of these horses (8 muscle samples) were homozygous or heterozygous for the MYH1 mutation (2 gluteal/epaxial and 6 SM/ST) and no significant differences were found when histopathology scores for MYH1 homozygotes (My/My) or heterozygotes (My/N) horses combined were compared to N/N horses.
| Nonexertional rhabdomyolysis 3.2.1 | NonER genotypes
Significantly, more nonER horses (111/165; 67%) possessed the E321G MYH1 mutation than controls (P < .001). NonER horses were both homozygous (75%) and heterozygous (25%) for the MYH1 mutation ( Figure 1 ). The MYH1 mutation was highly prevalent in nonER horses regardless of atrophy (39/42, 93% with atrophy; 72/123, 59%
without atrophy). The mutation for C7360G RYR1 was not present in any of the 81 nonER horses tested.
| NonER clinical signs
When specifically evaluating nonER horses with the MYH1 mutation, 65% (72/111) were not reported to have gross muscle atrophy and 35% (39/111) were reported to have atrophy. The MYH1 mutation increased the risk for muscle atrophy 12× in nonER horses (P < .001: OR 12.3). A history of fever was significantly more common in nonER horses with the MYH1 mutation (P < .038; odds ratio [OR], 7.6).
Weakness (P < .003; OR, 0.06) was less common in horses with the MYH1 mutation compared to nonER horses without the mutation.
The frequencies of recumbency, swollen muscles, stiffness, colic, or history of infection were not significantly different between nonER horses with and without the MYH1 mutation. Serum CK activities were markedly increased in nonER with maximum activities >1 million U/L in all genotypes (Figure 2 ). Log-transformed serum CK (P < .006) and AST (P < .001) activities were significantly higher in MYH1 heterozygotes and homozygotes compared to nonER horses without the mutation, with no significant differences between homozygotes and heterozygotes.
| NonER histopathology
Slides from 153 nonER muscle samples were available for evaluation.
The gluteal/epaxial muscles and the SM/ST muscles of My/My horses had significantly higher histopathologic scores for fiber size variation, anguloid atrophy, and centrally displaced myonuclei than N/N nonER horses ( Figures 3 and 4 , Table 2 ). Scores for acute myofiber degeneration, lymphocytic infiltrates, and macrophages were significantly higher in gluteal/epaxial muscles of My/My horses than in N/N nonER horses with no significant difference for these features between genotypes in SM/ST muscles ( Table 2 ). This finding agrees with comparisons of the 2 muscle groups within the same MYH1 homozygotes where the gluteal/epaxial muscles had significantly higher scores for acute necrosis, macrophages, and lymphocytes than did the SM/ST muscles (Table 3) Table 2 ). Fewer than 18% of horses with the MYH1 mutation had lymphocytic infiltrates in myofibers (Table 4 ) and the frequency of samples with lymphocytic (Table 4) . Total myopathic scores were significantly higher in My/My and My/N heterozygotes for gluteal/epaxial and SM/ST (Table 2) .
No significant differences were found in scores for PAS stain intensity, glycogen depletion in small myofibers, or abnormal cytoplasmic glycogen between My/My, My/N, or N/N nonER horses. However, significant differences were identified in scores for glycogen depletion in large myofibers of the gluteal/epaxial muscles across genotypes, with My/My horses having significantly higher scores than N/N nonER horses ( Figure 4 , Table 2 ). The number of horses with total glycogen depletion in large fibers of SM/ST also was higher in My/My versus N/N nonER horses (Table 4) . Subjectively, the largest fibers were typical type 2X fibers in N/N nonER horses, whereas in My/My horses, the largest fibers were typically type 2A fibers (Figure 4 ).
In myosin, ATPase stains of N/N horses, 3 distinct fiber types were readily distinguished (Figure 4) 
| DISCUSSION
The major finding in our study was the strong association between the E321G MYH1 mutation and nonER in QH-related breeds. In total, 67% of nonER QH possessed the MYH1 mutation compared to 5% of randomly selected healthy QH. Rhabdomyolysis in the nonER horses was severe with median serum CK activities above 30 000 U/L and maximal activities of over 1 million U/L, much higher than median activities previously reported for IMM. 1 Neither PSSM1, which affects FIGURE 3 Histopathological scores for skeletal muscle fiber type variation, anguloid atrophy, acute myofiber degeneration (myodegen), macrophages (macroph), and lymphocytes (lymph) in large myofibers in the gluteal muscle of horses homozygous (My/My), heterozygous (My/N), or unaffected (N/N) for the MYH1 mutation. *P < .05, **P < .01, ***P < .001 One of the previously reported features of muscle from IMM horses with the MYH1 mutation is immune-mediated lymphocytic destruction of type 2X muscle fibers, which comprise at least 60% of fibers in healthy gluteal muscle. 3 Both innate and adaptive immunity could trigger IMM. The innate immune response could drive reactivity Scores ranged from 0 to 3. Different letters indicate significant differences (P < .05) in scores across genotypes within the same muscle. Abbreviations: nonER, nonexertional rhabdomyolysis; ER, exertional rhabdomyolysis; Myodegen, myodegeneration; macroph., macrophage; lymph, lymphocytes. Scores ranged from 0 to 3. Different letters indicate significant differences (P < .05) in scores between muscles within the same genotype to self and affect the type of adaptive immune response that occurs when the mutant form of type 2X myosin heavy chain is released from myofibers after muscle damage (ER, trauma, and vaccination). 14, 15 Shared epitopes among bacteria, such as the M protein of group A Streptococcus spp. and the altered myosin in horses with the MYH1 mutation are potential instigators of an adaptive immune response. 3, 16 Of note, 2 young horses in our study that were homozygous and heterozygous for MYH1 were previously reported to have fatal S. equiassociated rhabdomyolysis. 17 This observation suggests that the MYH1 mutation may be the cause of previously reported S. equiassociated rhabdomyolysis in horses. Agents such as S. equi zooepidemicus, C. pseudotuberculosis, equine herpes virus, and equine influenza virus previously have been associated with triggering IMM and therefore potentially could be triggers for rhabdomyolysis in QH with the MYH1 mutation through the innate response either to primary muscle damage or by adaptive immunity. 14 Atrophy, fever, and infection in the presence of rhabdomyolysis appear to be strong indicators to perform MYH1 genetic testing in QH.
A confounding factor in connecting rhabdomyolysis to cellmediated destruction of type 2X fibers in our study was the fact that <18% of horses with the MYH1 mutation had lymphocytic infiltrates in muscle biopsies. The lack of lymphocytic infiltrates in many muscle samples suggests that either the cell-mediated immune reaction in skeletal muscle was not captured in the muscle biopsies evaluated or that an immune-mediated mechanism is not entirely responsible for rhabdomyolysis. The SM muscle alone was sampled in 48% of nonER horses and inflammatory infiltrates are more likely to be present in epaxial and gluteal muscles in IMM horses. myopathy, suggesting the mutation itself may be a cause of atrophy.
Mutations in MYH2 in humans, however, have not been associated with rhabdomyolysis.
Our study provided an indication the MYH1 mutation affect the activity of the myosin ATPase enzyme. The ATPase enzyme is located in the globular head of type 2X myosin near the site of the MYH1 mutation. 3 Modeling suggests that the E321G MYH1 mutation decreases contact between the SWITCH1 and helix 1 domains of the myosin 2X globular head and decreases stability of the protein. 3 This altered protein interaction could affect the myosin ATPase enzyme, which is commonly used in histochemical assays to detect fiber types.
In our study, IF staining and myosin ATPase assays both differentiated In conclusion, the E321G MYH1 mutation is strongly associated with nonER in QH-related breeds whether or not generalized muscle atrophy is present. Because most nonER horses with the MYH1 Letters indicate significant differences in glycogen depletion within the same muscle. No differences were found in the frequency of lymphocytes across genotypes. Different letters indicate significant differences (P < .05) in scores across genotypes within the same muscle mutation did not present with muscle atrophy or have lymphocytic infiltrates in muscle biopsy samples, we suggest that the term MYH1 myopathy (MYHM) be applied specifically to horses with atrophy or rhabdomyolysis that test positive for the MYH1 mutation. This term rather than IMM for horses with this genetic mutation eliminates the confusion about whether the underlying mechanism for rhabdomyolysis and atrophy is immune-mediated and distinguishes those inflammatory or immune-mediated myopathies that are not caused by the MYH1 mutation.
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